Desentum
  • Home
  • Technology
  • Company
  • News
  • Contact
  • Suomi
Select Page
Clinical study with birch pollen hypoallergen DM-101 continues

Clinical study with birch pollen hypoallergen DM-101 continues

by aisla@raikee.fi | Nov 30, 2020 | News

First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt. In early 2020, Desentum initiated a clinical study to evaluate the safety and tolerability of DM-101, a hypoallergen designed for treating birch pollen...
Clinical study with birch pollen hypoallergen DM-101 continues

First-in-Human clinical study with DM-101 paused due to corona virus pandemic

by aisla@raikee.fi | Mar 26, 2020 | News

Clinical study initiated in January 2020 with birch pollen hypoallergen DM-101 was suspended in March. The main reason for suspension is that the corona virus epidemic has brought about restrictions in the operations at the study site. In January, Desentum initiated a...
New scientific paper about hypoallergenic variants of horse allergen Equ c 1

New scientific paper about hypoallergenic variants of horse allergen Equ c 1

by aisla@raikee.fi | Jan 31, 2020 | News

The latest open access paper about our hypoallergen development is available at Nature Scientific Reports. The paper, titled “Development of hypoallergenic variants of the major horse allergen Equ c 1 for immunotherapy by rational structure based...
Desentum will run a clinical trial on its allergy vaccine this winter supported by 4 M€ of new investments

Desentum will run a clinical trial on its allergy vaccine this winter supported by 4 M€ of new investments

by aisla@raikee.fi | Nov 1, 2019 | News

Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve immunotherapeutic treatment of birch pollen allergy. In a funding round arranged by Springvest Oy, the company raised 4 million euros that it intends...
Clinical study with birch pollen hypoallergen DM-101 continues

Desentum aims to initiate clinical trials with its birch pollen allergy vaccine this fall

by aisla@raikee.fi | Sep 18, 2019 | News

Preparations are currently being finalized for the first clinical study with DM-101 hypoallergen, Desentum’s lead product candidate for the treatment of birch pollen allergy. DM-101 (rBet v 1 dm) is a genetically engineered birch pollen allergen that is designed to...
Desentum wins a 1.9 M€ EU grant for first-in-human clinical trials

Desentum wins a 1.9 M€ EU grant for first-in-human clinical trials

by aisla@raikee.fi | Oct 29, 2018 | News

Desentum has been awarded a 1.9 M€ grant from the EIC pilot SME Instrument for a project titled AllergyVAX. The two-and-a-half-year project, starting at the end of 2018, includes early clinical trials of Desentum’s lead product candidate, an immunotherapeutic vaccine...
« Older Entries
Next Entries »

Viimeisimmät artikkelit

  • Kutsu Desentum Oy:n varsinaiseen yhtiökokoukseen / Summons to Annual General Meeting of Desentum Oy
  • Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress
  • Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX
  • Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajille
  • Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland

Viimeisimmät kommentit

No comments to show.

DESENTUM OY

Tekniikantie 14, 02150 Espoo, Finland
info@desentum.fi

  • Follow
  • Follow

© Desentum Oy

Privacy policy
​​Cookie settings
Website: Räikee Oy

© Desentum Oy

Tietosuojaseloste
​​Evästeasetukset
Nettisivut: Räikee Oy